CClinicalTrials.gg
TerminatedNCT00118781Updated Jul 19, 2005

Trial of Iseganan in Prevention of Ventilator-Associated Pneumonia

A Phase 2/3 interventional study of iseganan hydrochloride in Pneumonia, sponsored by IntraBiotics Pharmaceuticals. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-07-19.

Sponsored by IntraBiotics Pharmaceuticals · Phase 2/3, Interventional, and Prevention

Phase
Phase 2/3
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multinational, double-blind, placebo-controlled trial designed to assess whether iseganan, applied topically to the oral cavity, can prevent ventilator-associated pneumonia among patients who are intubated and mechanically ventilated and survive for up to 14 days.

Read the detailed description

Patients will be randomized and receive their first dose of Study Drug within 24 hours of oral/nasal intubation and the initiation of mechanical ventilation. The Study Period will begin with the first administration of Study Drug (Study Day 1). Three mL of Study Drug (9 mg iseganan or matching placebo) will be applied to all visible surfaces in the oral cavity and the oral portion of the endotracheal tube (for non-tracheostomy patients) every 4 hours through Study Day 14, or until the diagnosis of microbiologically-confirmed pneumonia (based on central laboratory results) or extubation, whichever occurs first.

All patients will be evaluated for clinically defined pneumonia at least once daily and, if diagnosed, blood specimens will be collected and cultured, and a bronchoscopic alveolar lavage (BAL) specimen (for intubated patients) or a respiratory secretion specimen (for extubated patients) will be obtained PRIOR to initiating or changing any systemic antimicrobial therapy.

02

Conditions studied

  • Pneumonia

Keywords

  • ventilator-associated pneumonia
  • VAP
  • pneumonia
  • ICU infection
03

In context

Pneumonia

2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.

This study's enrollment of 900 is above the median of 106 across 1,247 interventional studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

This is the only study on the registry with IntraBiotics Pharmaceuticals as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Greater than or equal to 18 years of age
  • Orally/nasally intubated and receiving mechanical ventilation for \<24 hours prior to scheduled randomization and administration of the first dose of Study Drug, and in the judgment of the attending physician, expected to remain intubated and mechanically ventilated for at least 48 hours
  • Expected to survive for at least 21 days and to remain at the investigational site and not transferred to another institution while intubated during the 21-day study period
  • Willing and able to provide written informed consent, or if unconscious or have altered sensorium, have a surrogate provide written informed consent as approved by the institution
  • Negative pregnancy test within 7 days prior to randomization if a female of childbearing potential (Negative pregnancy test results [urine or serum] obtained for reason other than the purposes of this study are acceptable.)

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of pneumonia (Patients currently receiving antibiotics for treatment of pneumonia and patients who meet the study definition of clinically defined pneumonia at the time of screening will be excluded.)
  • Absolute neutrophil count less than 1000/mm3
  • Human immunodeficiency virus infection with a last known CD4 count less than 500/mm3
  • Recipient of organ transplantation and receiving immunosuppressive therapy
  • Current hematologic malignancy
  • Previously documented cystic fibrosis
  • Severe cranio-facial trauma or other medical condition expected to require imminent tracheostomy
  • Patient, patient's family and/or physician not in favor of aggressive medical management or presence of an advanced directive to withhold life-sustaining treatment
  • Moribund state or expected to survive less than 21 days due to an uncorrectable medical condition
  • Participation in a clinical trial of any unlicensed drug, biologic or device within 30 days prior to the first dose of study drug
  • Concurrent participation in a clinical trial of any unlicensed drug, biologic or device.
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Double
Enrollment
900 participants

Interventions

  • Drugiseganan hydrochloride
06

What researchers measure

Primary outcomes

  1. The primary objectives of this trial are to evaluate the safety and efficacy of iseganan when administered to intubated patients receiving mechanical ventilation.

Secondary outcomes

  1. The secondary objectives of this trial are to compare patients receiving iseganan to patients receiving placebo on the following: VAP-free survival through Day 21

  2. Days alive and free of parenteral antibiotic use through Day 14

  3. Days alive and free of mechanical ventilation through Day 14

07

Study locations

1 site
  • Barnes-Jewish Hospital
    St. Louis, Missouri 63110, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 19, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00118781
Lead sponsor
IntraBiotics Pharmaceuticals
First posted
Jul 12, 2005
Start date
Sep 2003
Completion
Jun 2004
Last update
Jul 19, 2005

Study contacts

Marin Kollef, MD
study chair · Barnes-Jewish Hospital, Washington University School of Medicine
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2005. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion